FDA Issues Black Box Warning for HCV Drugs

The FDA is calling on the manufacturers of direct-acting antiviral (DAA) agents to put “black box” warnings on their medication labels in the wake of recent reports of hepatitis B virus (HBV) resurfacing in patients who take the medications.